TrialsgrambetaRCTs are beautiful

FLAURA

2018

Osimertinib in Untreated EGFR-Mutated Advanced NSCLC

In 556 patients with untreated EGFR-mutated advanced NSCLC, osimertinib improved progression-free and overall survival compared with first-generation EGFR-TKI (gefitinib or erlotinib).

Result

Efficacy: Progression-free survivalHR 0.46

Below 1 favours osimertinib, above 1 favours first-generation EGFR-TKI (gefitinib or erlotinib).

Event rates Osimertinib 18.9 vs first-generation EGFR-TKI (gefitinib or erlotinib) 10.2 months

Also reported: OS 38.6 vs 31.8 months (HR 0.80).

Original publication
Subtopic
EGFR-mutant NSCLC
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Soria JC, et al. N Engl J Med. 2018;378(2):113-125; Ramalingam SS, et al. N Engl J Med. 2020;382(1):41-50.doi 10.1056/NEJMoa1713137

Discussion & critique

Established osimertinib as first-line standard in EGFR-mutated NSCLC; superseded by FLAURA2 (osimertinib + chemo) in fit patients with high-risk features.